A novel role for ATM in regulating proteasome- mediated protein degradation through suppression of the ISG15 conjugation pathway

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Wood, Laurence M ^a   Sankar, Surendran ^b   Reed, Ryan E ^b   Haas, Arthur L ^b   Liu, Leroy F ^c   McKinnon, Peter ^d   Desai, Shyamal D ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; INTERFERON STIMULATED GENE 15; MEMBRANE PROTEIN; UNCLASSIFIED DRUG; CELL CYCLE PROTEIN; CYTOKINE; DNA BINDING PROTEIN; G1P2 PROTEIN, MOUSE; ISG15 PROTEIN, HUMAN; PROTEASOME; PROTEIN; PROTEIN SERINE THREONINE KINASE; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN;

ARTICLE; ATAXIA TELANGIECTASIA; CONJUGATION; CONTROLLED STUDY; DNA REPAIR; GENE EXPRESSION REGULATION; GENE MUTATION; HUMAN; HUMAN TISSUE; INNATE IMMUNITY; NUCLEOTIDE SEQUENCE; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN PURIFICATION; UBIQUITINATION; ANIMAL; BRAIN; CELL CULTURE; METABOLISM; MOUSE; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY; UPREGULATION;

ATAXIA TELANGIECTASIA; MUS;

ANIMALS; ATAXIA TELANGIECTASIA; BRAIN; CELL CYCLE PROTEINS; CELLS, CULTURED; CYTOKINES; DNA-BINDING PROTEINS; HUMANS; MICE; MICE, KNOCKOUT; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN-SERINE-THREONINE KINASES; PROTEINS; TUMOR SUPPRESSOR PROTEINS; UBIQUITINS; UP-REGULATION;

EID: 79551510429     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016422     Document Type: Article

References (60)

1. Chun HH, Gatti RA (2004) Ataxia-telangiectasia, an evolving phenotype. DNA Repair (Amst) 3: 1187-1196.
2. Lavin MF, Scott S, Gueven N, Kozlov S, Peng C, et al. (2004) Functional consequences of sequence alterations in the ATM gene. DNA Repair (Amst) 3: 1197-1205.
3. McKinnon PJ (2004) ATM and ataxia telangiectasia. EMBO Rep 5: 772-776.
4. Boder E (1985) Ataxia-telangiectasia: an overview. Kroc Found Ser 19: 1-63.
5. Jentsch S, Pyrowolakis G (2000) Ubiquitin and its kin: how close are the family ties? Trends Cell Biol 10: 335-342.
6. Ritchie KJ, Zhang DE (2004) ISG15: the immunological kin of ubiquitin. Semin Cell Dev Biol 15: 237-246.
7. Narasimhan J, Potter JL, Haas AL (1996) Conjugation of the 15-kDa interferoninduced ubiquitin homolog is distinct from that of ubiquitin. J Biol Chem 271: 324-330.
8. Loeb KR, Haas AL (1992) The interferon-inducible 15-kDa ubiquitin homolog conjugates to intracellular proteins. J Biol Chem 267: 7806-7813.
9. Kim KI, Giannakopoulos NV, Virgin HW, Zhang DE (2004) Interferoninducible ubiquitin E2, Ubc8, is a conjugating enzyme for protein ISGylation. Mol Cell Biol 24: 9592-9600.
10. Dastur A, Beaudenon S, Kelley M, Krug RM, Huibregtse JM (2006) Herc5, an interferon-induced HECT E3 enzyme, is required for conjugation of ISG15 in human cells. J Biol Chem 281: 4334-4338.
11. Wong JJ, Pung YF, Sze NS, Chin KC (2006) HERC5 is an IFN-induced HECTtype E3 protein ligase that mediates type I IFN-induced ISGylation of protein targets. Proc Natl Acad Sci U S A 103: 10735-10740.
12. Zou W, Zhang DE (2006) The interferon-inducible ubiquitin-protein isopeptide ligase (E3) EFP also functions as an ISG15 E3 ligase. J Biol Chem 281: 3989-3994.
13. Zhao C, Beaudenon SL, Kelley ML, Waddell MB, Yuan W, et al. (2004) The UbcH8 ubiquitin E2 enzyme is also the E2 enzyme for ISG15, an IFN-alpha/ beta-induced ubiquitin-like protein. Proc Natl Acad Sci U S A 101: 7578-7582.
14. Yuan W, Krug RM (2001) Influenza B virus NS1 protein inhibits conjugation of the interferon (IFN)-induced ubiquitin-like ISG15 protein. EMBO J 20: 362-371.
15. Malakhov MP, Malakhova OA, Kim KI, Ritchie KJ, Zhang DE (2002) UBP43 (USP18) specifically removes ISG15 from conjugated proteins. J Biol Chem 277: 9976-9981.
16. D'Cunha J, Knight E, Jr., Haas AL, Truitt RL, Borden EC (1996) Immunoregulatory properties of ISG15, an interferon-induced cytokine. Proc Natl Acad Sci U S A 93: 211-215.
17. D'Cunha J, Ramanujam S, Wagner RJ, Witt PL, Knight E, et al. (1996) In vitro and in vivo secretion of human ISG15, an IFN-induced immunomodulatory cytokine. J Immunol 157: 4100-4108.
18. Padovan E, Terracciano L, Certa U, Jacobs B, Reschner A, et al. (2002) Interferon stimulated gene 15 constitutively produced by melanoma cells induces e-cadherin expression on human dendritic cells. Cancer Res 62: 3453-3458.
19. Owhashi M, Taoka Y, Ishii K, Nakazawa S, Uemura H, et al. (2003) Identification of a ubiquitin family protein as a novel neutrophil chemotactic factor. Biochem Biophys Res Commun 309: 533-539.
20. Harty RN, Pitha PM, Okumura A (2009) Antiviral Activity of Innate Immune Protein ISG15. J Innate Immun 1: 397-404.
21. Sadler AJ, Williams BR (2008) Interferon-inducible antiviral effectors. Nat Rev Immunol 8: 559-568.
22. Pitha-Rowe I, Hassel BA, Dmitrovsky E (2004) Involvement of UBE1L in ISG15 conjugation during retinoid-induced differentiation of acute promyelocytic leukemia. J Biol Chem 279: 18178-18187.
23. Malakhov MP, Kim KI, Malakhova OA, Jacobs BS, Borden EC, et al. (2003) High-throughput immunoblotting: ubiquitin-like protein ISG15 modifies key regulators of signal transduction. J Biol Chem 278: 16608-16613.
24. Hamerman JA, Hayashi F, Schroeder LA, Gygi SP, Haas AL, et al. (2002) Serpin 2a is induced in activated macrophages and conjugates to a ubiquitin homolog. J Immunol 168: 2415-2423.
25. Okumura A, Lu G, Pitha-Rowe I, Pitha PM (2006) Innate antiviral response targets HIV-1 release by the induction of ubiquitin-like protein ISG15. Proc Natl Acad Sci U S A 103: 1440-1445.
26. Okumura A, Pitha PM, Harty RN (2008) ISG15 inhibits Ebola VP40 VLP budding in an L-domain-dependent manner by blocking Nedd4 ligase activity. Proc Natl Acad Sci U S A 105: 3974-3979.
27. Malakhova OA, Zhang DE (2008) ISG15 inhibits Nedd4 ubiquitin E3 activity and enhances the innate antiviral response. J Biol Chem 283: 8783-8787.
28. Lu G, Reinert JT, Pitha-Rowe I, Okumura A, Kellum M, et al. (2006) ISG15 enhances the innate antiviral response by inhibition of IRF-3 degradation. Cell Mol Biol (Noisy-le-grand) 52: 29-41.
29. Haas AL (2006) ISG15-dependent Regulation In Protein Degradation. Mayer J, Ciechanover A, Rechsteiner R, eds. Weinheim, Germany: Wiley-VCH Verlag 5: 103-131.
30. Takeuchi T, Iwahara S, Saeki Y, Sasajima H, Yokosawa H (2005) Link between the Ubiquitin Conjugation System and the ISG15 Conjugation System: ISG15 Conjugation to the UbcH6 Ubiquitin E2 Enzyme. J Biochem (Tokyo) 138: 711-719.
31. Takeuchi T, Yokosawa H (2005) ISG15 modification of Ubc13 suppresses its ubiquitin-conjugating activity. Biochem Biophys Res Commun 336: 9-13.
32. Zou W, Papov V, Malakhova O, Kim KI, Dao C, et al. (2005) ISG15 modification of ubiquitin E2 Ubc13 disrupts its ability to form thioester bond with ubiquitin. Biochem Biophys Res Commun 336: 61-68.
33. Desai SD, Haas AL, Wood LM, Tsai YC, Pestka S, et al. (2006) Elevated expression of ISG15 in tumor cells interferes with the ubiquitin/26S proteasome pathway. Cancer Res 66: 921-928.
34. Desai SD, Wood LM, Tsai YC, Hsieh TS, Marks JR, et al. (2008) ISG15 as a novel tumor biomarker for drug sensitivity. Mol Cancer Ther 7: 1430-1439.
35. Siddoo-Atwal C, Haas AL, Rosin MP (1996) Elevation of interferon betainducible proteins in ataxia telangiectasia cells. Cancer Res 56: 443-447.
36. Ardley HC, Hung CC, Robinson PA (2005) The aggravating role of the ubiquitin-proteasome system in neurodegeneration. FEBS Lett 579: 571-576.
37. Finkbeiner S, Mitra S (2008) The ubiquitin-proteasome pathway in Huntington's disease. Scientific World Journal 8: 421-433.
38. Lehman NL (2009) The ubiquitin proteasome system in neuropathology. Acta Neuropathol 118: 329-347.
39. Lim KL (2007) Ubiquitin-proteasome system dysfunction in Parkinson's disease: current evidence and controversies. Expert Rev Proteomics 4: 769-781.
40. Oddo S (2008) The ubiquitin-proteasome system in Alzheimer's disease. J Cell Mol Med 12: 363-373.
41. Paul S (2008) Dysfunction of the ubiquitin-proteasome system in multiple disease conditions: therapeutic approaches. Bioessays 30: 1172-1184.
42. Eilam R, Peter Y, Groner Y, Segal M (2003) Late degeneration of nigro-striatal neurons in ATM-/- mice. Neuroscience 121: 83-98.
43. Wu X, Ranganathan V, Weisman DS, Heine WF, Ciccone DN, et al. (2000) ATM phosphorylation of Nijmegen breakage syndrome protein is required in a DNA damage response. Nature 405: 477-482.
44. Tscherne JS, Pestka S (1975) Inhibition of protein synthesis in intact HeLa cells. Antimicrob Agents Chemother 8: 479-487.
45. Ikeda F, Dikic I (2008) Atypical ubiquitin chains: new molecular signals. 'Protein Modifications: Beyond the Usual Suspects' review series. EMBO Rep 9: 536-542.
46. Menendez-Benito V, Verhoef LG, Masucci MG, Dantuma NP (2005) Endoplasmic reticulum stress compromises the ubiquitin-proteasome system. Hum Mol Genet 14: 2787-2799.
47. Brignone C, Bradley KE, Kisselev AF, Grossman SR (2004) A postubiquitination role for MDM2 and hHR23A in the p53 degradation pathway. Oncogene 23: 4121-4129.
48. Ulane CM, Kentsis A, Cruz CD, Parisien JP, Schneider KL, et al. (2005) Composition and assembly of STAT-targeting ubiquitin ligase complexes: paramyxovirus V protein carboxyl terminus is an oligomerization domain. J Virol 79: 10180-10189.
49. Chen S, Wang G, Makrigiorgos GM, Price BD (2004) Stable siRNA-mediated silencing of ATM alters the transcriptional profile of HeLa cells. Biochem Biophys Res Commun 317: 1037-1044.
50. Ross CA, Pickart CM (2004) The ubiquitin-proteasome pathway in Parkinson's disease and other neurodegenerative diseases. Trends Cell Biol 14: 703-711.
51. Jana NR, Zemskov EA, Wang G, Nukina N (2001) Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Hum Mol Genet 10: 1049-1059.
52. Agamanolis DP, Greenstein JI (1979) Ataxia-telangiectasia. Report of a case with Lewy bodies and vascular abnormalities within cerebral tissue. J Neuropathol Exp Neurol 38: 475-489.
53. McKinnon PJ (2009) DNA repair deficiency and neurological disease. Nat Rev Neurosci 10: 100-112.
54. Bergink S, Jentsch S (2009) Principles of ubiquitin and SUMO modifications in DNA repair. Nature 458: 461-467.
55. Pamment J, Ramsay E, Kelleher M, Dornan D, Ball KL (2002) Regulation of the IRF-1 tumour modifier during the response to genotoxic stress involves an ATM-dependent signalling pathway. Oncogene 21: 7776-7785.
56. Ashburner BP, Shackelford RE, Baldwin Jr. AS, Paules RS (1999) Lack of involvement of ataxia telangiectasia mutated (ATM) in regulation of nuclear factor-kappaB (NF-kappaB) in human diploid fibroblasts. Cancer Res 59: 5456-5460.
57. Desai SD, Li TK, Rodriguez-Bauman A, Rubin EH, Liu LF (2001) Ubiquitin/ 26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells. Cancer Res 61: 5926-5932.
58. Haas AL, Ahrens P, Bright PM, Ankel H (1987) Interferon induces a 15- kilodalton protein exhibiting marked homology to ubiquitin. J Biol Chem 262: 11315-11323.
59. Herzog KH, Chong MJ, Kapsetaki M, Morgan JI, McKinnon PJ (1998) Requirement for Atm in ionizing radiation-induced cell death in the developing central nervous system. Science 280: 1089-1091.
60. Sakaguchi A, Kikuchi A (2004) Functional compatibility between isoform alpha and beta of type II DNA topoisomerase. J Cell Sci 117: 1047-1054.